Pakistan heart study finds widespread cardiac risks in adults AI-generated image

Pakistan heart study finds widespread cardiac risks in adults

Newsora24 staff
3 minRead
0Views
0Reading now

Cardiologists said on Saturday that preliminary results from Pakistan’s first comprehensive study of 2,000 healthy adults with no disease symptoms point to widespread heart risks. According to the findings, 78 per cent of participants are obese, 33 per cent have hypertension and 22 per cent have diabetes, while another 23 per cent are prediabetic.

Dr Bashir Hanif, the study’s principal investigator, presented the baseline results at the primary prevention session of the 55th CardioCon at the Serena Hotel on Saturday.

Obesity, cholesterol and family history findings

Hanif said obesity, measured with an Asian BMI cut-off of 25, was found in 81 per cent of women and 74 per cent of men. He added that 32 per cent of participants reported a family history of premature coronary heart disease, and 68 per cent had low levels of “good” HDL cholesterol.

He stressed that risk factors seldom appear alone. Hypertension, dyslipidaemia, obesity and diabetes often coexist in the same people, and the more of these a person carries, the greater the amount of silent atherosclerosis. “Calcium was found in the coronary arteries of 26 per cent of participants,” he said, warning that conventional clinical risk assessment could underestimate the disease already present.

Pakistan heart study finds widespread cardiac risks in adults
AI-generated illustration

Design of the PAK-SEHAT cohort study

The Pakistan Study of Premature Coronary Atherosclerosis in Young Adults, known as PAK-SEHAT, is a prospective cohort study run jointly by the Fatima Hanif Foundation and Getz Pharma. The pharmaceutical company provided an unrestricted research grant to launch the project. It has been described as the first study of its kind in the country and has been nicknamed a “mini Framingham” of Pakistan, a reference to the landmark US heart study.

Men aged 35 to 60 and women aged 35 to 65 were enrolled from all four provinces and Islamabad through eight centres, and none of them had symptomatic cardiovascular disease. Hanif said their average age was 39. Baseline assessments include blood tests, carotid ultrasound and coronary CT angiography, and participants will be followed for five years.

Early heart disease and gaps in South Asian research

Dr Khurram Nasir, co-principal investigator and chief of the Division of Cardiovascular Prevention and Wellness at Houston Methodist, said PAK-SEHAT could become a “gold mine” of data for Pakistan. He said South Asians, especially Pakistanis, have remained largely “invisible” in global research, leaving little known about the causes, early onset and risk factors of heart disease in these populations.

Nasir, who is also editor-in-chief of the American Journal of Preventive Cardiology, said the early results suggested that being a man aged 35 or older was itself a risk factor for Pakistanis. He linked this possibly to sedentary lifestyles, genetics and environmental factors, and said further details would be released once the study was finalised. He also said heart disease appeared to start 10 to 15 years earlier in Pakistanis than in other groups, and that the reasons for early heart attacks and deaths among younger people and men had never been investigated.

Getz Pharma frames study as a national prevention blueprint

Kashif Amin, Head of Public Health at Getz Pharma, said cardiovascular disease claims lives quietly in Pakistan. He argued that guidelines and risk-scoring models have relied on Western data, so prevention must be built on the country’s own evidence. He said the company’s vision extends beyond medicines, aiming to move care from late-stage treatment toward primary prevention.

Amin described PAK-SEHAT as a national blueprint for protecting Pakistan’s youth, workforce and families. He said Getz Pharma would continue linking clinicians, investigators and the public. Nasir, for his part, paid tribute to Hanif and Getz Pharma for making the study possible.

Leave an opinion

Your email address will not be published. Required fields are marked *

Story saved